The Utility of Older Generic Medicines in the Current Practice of Dermatology

In this presentation, Liz Jones discusses the use of older generic medications, dapson and colchicine, in dermatologic practice, emphasizing their cost-effectiveness and suitability for patients who are underinsured or uninsured. Both medications are considered in cases requiring minimized immunosuppression, particularly when ruling out malignancies in patients already on other immunosuppressive therapies. Dapsone primarily inhibits neutrophilic chemotaxis and is effective in conditions characterized by neutrophilic infiltration, such as sweet syndrome and pyoderma gangrenosum. It is used as a first-line treatment for specific inflammatory skin disorders, while its side effects—including hemolytic anemia and methemoglobinemia—necessitate careful monitoring, especially regarding patients' G6PD status. Colchicine is another medication with limited FDA-approved uses but is occasionally effective for rare dermatological conditions, with attention needed for dosage adjustments, especially in the elderly or those with renal impairment. Both medications involve monitoring and awareness of potential side effects and interactions, particularly in patients on multiple medications. Jones stresses the importance of patient education, monitoring for adverse reactions, and understanding the unique pharmacological profiles and dosing strategies of these medications in dermatological treatment.